Friday, 15 Dec 2017

You are here

The RheumNow Week in Review - 17 November 2017

Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. This week he covers FDA warnings on gout drugs, steroid use in Australia, biosimilars lost savings and methotrexate hepatotoxicity in psoriatic arthritis (PsA).

  1. HTN redefined as 130/80!! The American Heart Association estimates the change will mean 46 percent of adults in the USA have HTN https://t.co/zVPZN8JaiX
  2. 3699 RA pts in Australian registry show decreasing pred use from 2001-2015 (55%--39%). Corticosteroid use is  associated with use of DMARDs/NSAID/opioids, higher disease activity, lower pain scores, worse HAQ scores BUT was NOT associated w/ biologic use. https://t.co/UJxn1Wbzi1
  3. IL-17–producing αβ T cell clones with psoriasis-specific antigen receptors exist in clinically resolved psoriatic skin lesions and represent the disease-initiating pathogenic T cells in psoriasis. https://t.co/Lj4B4dQ25N
  4. Abbvies 9/17 settlement with Amgen that allows Amgens adalimumab biosimilar (Amjevita) to begin sales in EU Oct 2018 and in the USA in 2023 is estimated to cost the US Centers of Medicare and Medicaid (CMS) at least US$1.48 billion in savings. … https://t.co/S21dfEjadJ
  5. FDA issues a Safety Alert over FEBUXOSTAT and increased risk of Cardiac Death (compared to allopurinol users). This is based on comparative 6000 pt safety trial wherein Febuxostat showed an increased risk of heart-related deaths and death from all causes. https://t.co/3clsintj7L
  6. Smoking Paradox in PsA -  a UK study shows smoking was positively related to PsA risk in the general population (HR 1.27), but negatively associated with PsA risk among patients with psoriasis (HR 0.91). https://t.co/N7ZEgUYHhH
  7. Metanalysis of 6 studies, 7908 controls and 2899 cases, showed that vitamin C intake was associated with lower risk of hip fracture [OR = 0.73, 95% CI = 0.55-0.97].  A 50 mg/d increase in vitamin C intake statistically reduced by hip Fx risk by 5%  https://t.co/k9qD4YySiX
  8. Pregabalin (not duloxetine) improves pain in hand osteoarthritis in RCT vs PBO - improved pain and function. https://t.co/Hio2wfWLKx
  9. Stroke Increased in Rheumatoid Arthritis  
  10. MTX Doubles Hepatotoxicity Risk in Psoriasis Patients 
  11. Thiopurines and Anti-TNF drugs in IBD Associated with Increased Lymphoma Risk  
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

The RheumNow Week in Review - 15 December 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com. 

The RheumNow Week in Review - 8 December 2017

Dr. Jack Cush covers the news and journal articles published on RheumNow.comin the past week.

Rheumatology Year in Review

During 2017, the improvements and refinements seen during previous years in the treatment of rheumatoid arthritis have been extending to other conditions ranging from psoriatic arthritis to lupus and for both monoclonal antibodies and oral small molecule medications.

Advances for Biologics

The ACR17 RheumNow Week in Review - 1 December 2017

Dr Jack Cush reviews nighlights and news from the past 2 weeks on RheumNow.com. This week's report includes new drug approvals, disappointing ACR guidelines, Lyme & Zika, infertility, dermatomyositis skin outcomes and myositis-associated cancer testing.

ACR Clinical Guidelines Flawed by Low Evidence

JAMA Internal Medicine has reported that recommendations and clinical practice guidelines from the American College of Rheumatology are often based on expert opinion, but lack rigorous (grade A) evidence to support many of their recommendations.